SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following news of a major multi-year AI infrastructure deal with Microsoft, driving significant after-hours gains. The community is discussing the potential impact on valuation and future partnerships, particularly in the context of the hyperscale data center race. Some are speculating on the likelihood of a capital raise to support the deal's infrastructure demands.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) is trending due to a significant surge, reportedly linked to news of a private placement and strategic investment related to a crypto initiative. The community is actively discussing the stock's massive intraday gains, potential short squeeze dynamics, and comparisons to other high-flying tickers. Some traders express skepticism, pointing to the company's fundamentals and potential dilution, while others remain bullish, anticipating further upside.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to anticipation surrounding an upcoming merger vote, with the community buzzing about the potential for a significant short squeeze and comparing it to other high-momentum plays. Bullish sentiment is fueled by the company's move to become a Bitcoin treasury asset manager and potential access to substantial funding, while others are wary of potential dilution post-merger.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending due to a live demonstration of their solid-state batteries powering a Ducati motorcycle, showcasing faster charging and higher energy density, which has excited the community. Discussions revolve around the potential for mass production and partnerships with major automakers, as well as the possibility of a short squeeze given the stock's high short interest. Some investors believe this validates the long-term potential of solid-state battery technology in the EV sector.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending as investors discuss its potential for a short squeeze and potential major partnership announcements, fueled by recent strong revenue growth and expansion into the healthcare sector. The community highlights the company's unique position in voice AI, particularly its integration with NVIDIA chips, and anticipates further catalysts from the CFO's upcoming conference appearance. Bullish sentiment is strong, with some speculating on significant price appreciation and long-term growth.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

SNTG is trending as traders discuss its potential for a significant run, drawing comparisons to recent surges in similar stocks like OCTO. Community members highlight SNTG's low float and potential for a short squeeze, fueling speculative interest. Some traders are also pointing to a potential for increased borrow fees, which could add pressure on shorts.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

XVM.X is trending as a relatively new crypto, with users actively discussing its potential for high returns and its possible integration with real-world assets; the community is also weighing in on where to purchase it and some are concerned about whether it is a legitimate project or a 'rug pull'.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics, Inc. (PTCT) said on Tuesday that the U.S. Food and Drug Administration refused to approve its application for Vatiquinone for the treatment of children and adults living with Friedreich's ataxia.CEO Matthew B. Klein said that the company is disappointed by the FDA’s decision and plans to meet with the agency to discuss potential steps to address the issues flagged in its complete response letter to the company.In its <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-complete-response-letter-vatiquinone">letter</a>, the FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission. Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disease that primarily affects the nervous system, causing progressive damage to the spinal cord, peripheral nerves, and cerebellum. This leads to impaired muscle coordination, balance problems, and other neurological symptoms.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PTCT">PTCT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_12_18_34_PM_png_b76ebe8504.webp" alt="PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="61"><figcaption>PTCT's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock trading in the green despite the news.<stembedurl>https://stocktwits.com/deadlypants/message/625768448</stembedurl>TD Cowen analyst Joseph Thome lowered their price target on PTC Therapeutics to $50 from $56 while keeping a ‘Hold’ rating on the shares following the company’s update. The firm removed Friedreich's ataxia from its model and believes a second successful late-stage study will likely be required for approval.RBC Capital, which has an ‘Outperform’ rating and $63 price target on the stock, meanwhile, believes this was generally expected and already baked into the stock. The firm said that it would still buy the company's shares, according to TheFly.Jefferies analyst Kelly Shi also lowered the firm's price target on PTC Therapeutics to $63 from $64 while keeping a ‘Buy’ rating on the shares. The letter "didn't come in as a surprise to us," said the analyst, who calls the regulatory update "a clearing event" that allows investors to now focus on the launch of a treatment for phenylketonuria.&nbsp;PTCT stock is up by 14% this year and by about 50% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iovance-stock-rises-on-health-canada-approval-for-cancer-immunotherapy/chsgV4qRdW2">Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a PTC Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.

Equity

The FDA stated that substantial evidence of efficacy was not demonstrated for Vatiquinone and that an additional adequate and well-controlled study would be needed to support application resubmission.


PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Retail chatter around PTC Therapeutics surged Monday after the FDA approved Sephience (sepiapterin) for the treatment of phenylketonuria (PKU), a rare genetic disorder that disrupts the body’s ability to break down phenylalanine.&nbsp;The decision grants broad labeling for use in adults and children as young as one month who are responsive to sepiapterin.The approval was supported by results from the Phase 3 Aphenity trial and its long-term extension, which showed significant reductions in blood phenylalanine levels and sustained treatment effects.&nbsp;Sephience is designed to address hyperphenylalaninemia (HPA) across all PKU subtypes.The U.S. decision follows European Commission (EC) marketing authorization last month, which also granted a broad label across all ages and disease severities.&nbsp;PTC described the EC approval as a “great step” toward making Sephience available globally for patients with PKU.Analysts had been closely monitoring the regulatory timeline.&nbsp;Citi raised its price target on PTC Therapeutics to $50 from $40 earlier this month, adding a 30-day "upside catalyst watch" in anticipation of the FDA decision. The firm maintained a Neutral rating and noted it remains cautious about Sephience’s longer-term sales potential.On Stocktwits, retail sentiment for PTC Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/PTCT">PTC Therapeutics’ stock</a> has declined 3.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around PTC Therapeutics (PTCT) surged Monday after the FDA approved Sephience (sepiapterin) for the treatment of phenylketonuria. (Photo credit: Getty Images)

FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened

The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels.

Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Current Price	$56.95
Prev Close	$57.26
Open	$56.88
Dividend Yield	0.00%
50-Day Moving Average	$49.27
Beta	1.05
Avg. Volume	1.25M
PE Ratio	8.21

52-Week High	$58.73
52-Week Low	$30.98
Market Capitalization	$4.55B
EPS (Annual)	-$4.73
Price to Book	-22.01
Revenue Per Employee	$859,190.63
Enterprise Value/EBITDA	N/A

PTCT
PTC Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTCT News

PTCT PTC Therapeutics Inc